Intuitive Surgical, the dominant player in surgical robotics, demonstrated robust operational momentum in 2025 as its da Vinci system installed base expanded 12% to 11,106 units globally. The company reported an 18% year-over-year increase in surgeries performed using its flagship platform, underscoring sustained demand for minimally invasive surgical solutions across healthcare systems worldwide.
The company's financial trajectory remains largely independent of the pharmaceutical industry's focus on GLP-1 weight loss medications from competitors Novo Nordisk and Eli Lilly. Intuitive Surgical's performance reflects broad adoption of robotic-assisted surgery across multiple procedure types and specialties, rather than reliance on any single therapeutic category or market trend.
Trading at a price-to-earnings ratio of 61, Intuitive Surgical's valuation remains below its five-year historical average of 71, according to current market data. The valuation differential reflects potential investor appetite for exposure to the company's technological roadmap, which includes artificial intelligence integration and future advancements in autonomous surgical capabilities.